Cellectar Biosciences enrolled its first patient in its Phase 1b clinical trial evaluating iopofosine I 131 in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG), the company announced…
Cellectar Biosciences has partnered with Meaningful Insights-BioTech Analytics (MiBA), a data subsidiary of American Oncology Network (AON), the organization announced today. According to a release, the partnership will look to…
Cellectar Biosciences has expanded its licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin…
Cellectar Biosciences is partnering with Florida Cancer Specialists & Research Institute (FCS) to advance patient care and further define the U.S. treatment landscape, the company announced today. According to a…
Cellectar Biosciences has closed its $103 million private placement financing, the company announced today. According to a release, the financing was led by Rosalind Advisors with participation from AIGH Capital,…
Cellectar Biosciences has been awarded $1.98 million in additional grant funding by the National Institute of Health’s National Cancer Institute (NCI), the company announced today. According to a release, the…
Cellectar Biosciences has been awarded a $2 million Phase II National Institutes of Health (NIH) SBIR grant from the National Cancer Institute (NCI), the company announced recently. According to a…
Cellectar Biosciences and LegoChemBio, a clinical-stage biotechnology company in South Korea, have entered a development and commercialization collaboration, the company announced today. According to a release, the two companies have…
Cellectar Biosciences has received another patent by the Japanese Patent Office, this time for its proprietary phospholipid-ether (PLE), the company announced today. According to a release, the patent provides composition…
The European Commission has granted Cellectar Biosciences orphan drug designation and 10 years of European market exclusivity for CLR 131 in Waldenstrom’s Macroglobulinemia (WM), the company announced today. “Receipt of European orphan…
